BIOTEN HISTORY
At Bioten, our journey has been dedicated to the
health and well-being of humanity.
health and well-being of humanity.
-
- ~2023
-
-
- 2024
-
- Tencumin S Plus IRB approval for colon cancer clinical trial at Konyang University
- Technology transfer agreement for compositions for the prevention or treatment of colon cancer
- Acquisition of Biotene Co., Ltd. Yeonggwang factory assets.
- Technology transfer agreement for compositions for preventing, improving or treating obesity
- Signed a product supply contract with LH Korea in China
-
- 2023
-
- KONEX listing
- Launched our original brand, 'TenQmin'
- Research findings on the potential treatment of COVID-19 were published in the February issue of the International Journal of Immunopharmacology
-
- 2022
-
- Achieved annual sales exceeding 10 billion won in 2022
-
- 2021
-
- Initiated exports to Chile, Bangladesh, and Taiwan
- Selected for a pilot project in Jeollabuk-do for reducing avian influenza (AI)
-
- 2020
-
- Concluded manufacturing, sales, and supply agreement with PharmGen Science Corp. (formerly Wooridul Pharmaceuticals, Inc.)
- Successfully obtained IND approval for Phase 1 clinical trials of a rotavirus treatment
-
-
- 2017 ~ 2019
-
-
- 2019
-
- Designated as a member of the Korea Institute of Life Sciences family of enterprises
-
- 2017
-
- Concluded a technology transfer agreement for a composition for the prevention or treatment of rotavirus (with the Korea Institute of Life Sciences)
-
-
- 2014 ~ 2016
-
-
- 2016
-
- Concluded a technology transfer agreement for the solubilization technology of hydrophobic substances
(with the Korea Institute of Life Sciences) - Selected as a supported company for the Korea Institute of Life Sciences' Creative Technology Commercialization Project
(Emerging Hidden Champions)
- Concluded a technology transfer agreement for the solubilization technology of hydrophobic substances
-
- 2015
-
- Certified as a technology innovation-oriented small and medium enterprise (Innobiz)
-
- 2014
-
- Acquired ISO 9001 certification
-
-
- 2011 ~ 2013
-
-
- 2013
-
- Concluded a technology transfer agreement for the immune-boosting material KR-500
(with the Korea Institute of Life Sciences)
- Concluded a technology transfer agreement for the immune-boosting material KR-500
-
- 2012
-
- Achieved venture company certification
- Accomplished overseas exports (to Malaysia)
- Applied for manufacturing authorization of veterinary ancillary products (disinfectants)
-
- 2011
-
- Concluded a technology transfer agreement for the antiviral material KW-100
(with the Korea Institute of Life Sciences) - Established an in-house research and development center
- Company establishment (Bioten)
- Concluded a technology transfer agreement for the antiviral material KW-100
-
